Axogen Completes BioCircuit Acquisition to Expand Nerve Repair Portfolio

Key Facts

1Axogen completed the acquisition of BioCircuit Technologies to integrate NerveTape technology into its portfolio.

2NerveTape is the first FDA-cleared device for sutureless peripheral nerve repair.

Axogen completed the acquisition of BioCircuit Technologies to integrate NerveTape technology into its portfolio. GlobeNewswire reported that NerveTape is the first FDA-cleared device for sutureless peripheral nerve repair, allowing the company to offer advanced surgical solutions that eliminate the need for traditional sutures.

The acquisition aims to expand Axogen's product line in the peripheral nerve repair market by adding a sutureless surgical solution. The company expects BioCircuit to contribute approximately $6 million to fourth-quarter 2026 revenue and approximately $34 million to 2027 revenue, while maintaining a full-year 2026 gross margin target of at least 73%.